MarketCap
Facebook
X
Telegram
Monopar Therapeutics Balance Sheet 2025-2011 | MNPR
Brief balance sheet overview of Monopar Therapeutics
The comparison uses five available annual reports from the 2021–2025 interval.
Assets rose from $20.5 million to $140.7 million, a gain of +585.7%, while CAGR was about 61.8%. The balance sheet expanded rapidly.
Liabilities grew more slowly than assets: +82.9% versus +585.7%. Expansion relied more on equity, improving funding quality.
Equity funds 97.9% of assets versus 92.3% initially. This creates a conservative balance sheet structure.
The balance sheet holds more cash than interest-bearing debt; net debt is -$61.6 million, indicating minimal leverage.
Cash equals 43.9% of the balance sheet, compared with 98.9% five periods ago. This is the readily available cushion.
The accumulated result is -$89.5 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
What the balance sheet shows
Monopar Therapeutics has a solid balance sheet cushion. Capital and liquidity support development without excessive reliance on debt.
Annual Balance Sheet Monopar Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-61.6 M | - | - | -8.18 M | - | -16.7 M | -13.2 M | -6.89 M | -8.98 M | -2.07 M | - | - | - | - | - |
Long Term Debt |
155 K | - | - | 8.41 K | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
90.6 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Current Liabilities |
2.74 M | 5.25 M | 1.76 M | 3.13 M | 1.58 M | 1.18 M | 724 K | 400 K | 312 K | - | - | - | - | - | - |
Total Liabilities |
2.89 M | 5.25 M | 1.76 M | 3.14 M | 1.58 M | 1.18 M | 724 K | 400 K | 312 K | 64.5 K | - | - | - | - | - |
Retained Earnings |
-89.5 M | -75.8 M | -60.2 M | -51.8 M | -41.3 M | -32.2 M | -25.9 M | -21.7 M | -18.4 M | -1.87 M | - | - | - | - | - |
Total Assets |
141 M | 60.3 M | 7.35 M | 13.2 M | 20.5 M | 16.9 M | 13.4 M | 7.32 M | 9.93 M | 2.9 M | - | - | - | - | - |
Cash and Cash Equivalents |
61.8 M | 45.8 M | 7.27 M | 8.19 M | 20.3 M | 16.7 M | 13.2 M | 6.89 M | 8.98 M | 2.87 M | - | - | - | - | - |
Book Value |
138 M | 55 M | 5.59 M | 10.1 M | 18.9 M | 15.7 M | 12.6 M | 6.92 M | 9.62 M | 2.83 M | - | - | - | - | - |
Total Shareholders Equity |
138 M | 55 M | 5.59 M | 10.1 M | 18.9 M | 15.7 M | 12.6 M | 6.92 M | 9.62 M | 2.83 M | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Monopar Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
80.4 K | 132 K | - | 70.9 K | 80.4 K | - | - | - | - | - | - | - | - | - | 8.41 K | 20.8 K | 33.1 K | 25.3 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 54.6 K | 75 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
2.89 M | 2.59 M | 5.25 M | 2.64 M | 1.66 M | 1.49 M | 5.25 M | 1.12 M | 1.09 M | - | 1.76 M | 1.98 M | 2.5 M | 2.89 M | 3.14 M | 1.94 M | 2.22 M | 1.1 M | 1.58 M | 1.24 M | 1.1 M | - | 1.18 M | 1.18 M | 1.18 M | 444 K | 724 K | 724 K | 724 K | 724 K | 400 K | 400 K | 400 K | 400 K | 312 K | 312 K | 312 K | 312 K | 64.5 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-89.5 M | -93.4 M | -75.8 M | -84.3 M | -80.9 M | -78.4 M | -75.8 M | -64.9 M | -63.6 M | - | -60.2 M | -58.4 M | -56.4 M | -54.2 M | -51.8 M | -48.9 M | -46.5 M | -43.7 M | -41.3 M | -38.6 M | -36.1 M | -34.1 M | -32.2 M | -32.2 M | -32.2 M | -32.2 M | -25.9 M | -25.9 M | -25.9 M | -25.9 M | -21.7 M | -21.7 M | -2.4 K | -21.7 M | -18.4 M | -18.4 M | -18.4 M | -18.4 M | -1.87 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
141 M | 138 M | 60.3 M | 144 M | 53.9 M | 55.1 M | 60.3 M | 6.07 M | 7.18 M | - | 7.35 M | 8.59 M | 10.3 M | 11.8 M | 13.2 M | 14.4 M | 16.7 M | 18.1 M | 20.5 M | 22.5 M | 24.5 M | 25.9 M | 16.9 M | 16.9 M | 16.9 M | 16.9 M | 13.4 M | 13.4 M | 13.4 M | 13.4 M | 7.32 M | 7.32 M | 7.32 M | 7.32 M | 9.93 M | 9.93 M | 9.93 M | 9.93 M | 2.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
61.8 M | 52.5 M | 45.8 M | 128 M | 39.5 M | 39.7 M | 45.8 M | 6.02 M | 6.12 M | - | 7.27 M | 5.52 M | 7.21 M | 5.73 M | 8.19 M | 14.3 M | 16.5 M | 17.8 M | 20.3 M | 22.3 M | 24.3 M | 25.7 M | 16.7 M | 16.7 M | 16.7 M | 16.7 M | 13.2 M | 13.2 M | 13.2 M | 13.2 M | 6.89 M | 6.89 M | 6.89 M | 6.89 M | 8.98 M | 8.98 M | 8.98 M | 8.98 M | 2.07 M | - | - | - | 2.81 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
138 M | 135 M | 55 M | 142 M | 52.2 M | 53.6 M | 55 M | 4.95 M | 6.09 M | - | 5.59 M | 6.61 M | 7.84 M | 8.94 M | 10.1 M | 12.5 M | 14.5 M | 17 M | 18.9 M | 21.3 M | 23.4 M | 25.9 M | 15.7 M | 15.7 M | 15.7 M | 16.4 M | 12.6 M | 12.6 M | 12.6 M | 12.6 M | 6.92 M | 6.92 M | 6.92 M | 6.92 M | 9.62 M | 9.62 M | 9.62 M | 9.62 M | 2.83 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
55 M | 135 M | 5.59 M | 142 M | 52.2 M | 53.6 M | 55 M | 4.95 M | 6.09 M | 7.48 M | 5.59 M | 6.61 M | 7.84 M | 8.94 M | 10.1 M | 12.5 M | 14.5 M | 17 M | 18.9 M | 21.3 M | 23.4 M | 25.1 M | 15.7 M | 15.7 M | 15.7 M | 15.7 M | 12.6 M | 12.6 M | 12.6 M | 12.6 M | 6.92 M | 6.92 M | 6.92 M | 6.92 M | 9.62 M | 9.62 M | 9.62 M | 9.62 M | 2.83 M | - | - | - | 2.75 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Monopar Therapeutics , providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
China
Britain
France
Israel
Germany
Russia
Belgium
Cayman-islands
